
               
               
               7 DRUG INTERACTIONS
               
               
                  
                     
                     
                     7.1     Effects of Other Drugs on ZONTIVITY
                     
                        Vorapaxar is eliminated primarily by metabolism, with contributions from CYP3A4 and CYP2J2.
                     
                     
                     
                        
                           
                           
                           
                              
                                 Strong CYP3A Inhibitors
                              
                              Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
                           
                           
                        
                     
                     
                        
                           
                           
                           
                              
                                 Strong CYP3A Inducers
                              
                              Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
                              
                           
                           
                        
                     
                  
               
            
         